Docoh
Loading...
Sign up Log in

AMGN AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Company profile

Ticker
AMGN
Exchange
NASDAQ
Website
www.amgen.com/
CEO
Robert Bradway
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Dec 31
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
Biological Products, (No Diagnostic Substances)
Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics • Innate Pharma ...
Former names
AMGEN
SEC CIK
0000318154
Corporate docs
IRS number
953540776

AMGN stock data

(
)

News

Pro users get this 30m faster
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
16 Apr 21
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
16 Apr 21
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Is Silicon Valley Replacing Big Pharma In Neuroscience?
6 Apr 21
The following article is sponsored by Mind Cure. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.
Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $275
5 Apr 21
The Latest Picks And Pans From Barron's: Barrick Gold, BioNTech, Facebook, WW And More
4 Apr 21

Press releases

Pro users get this 30m faster
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
16 Apr 21
THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of
Amgen to Acquire Rodeo Therapeutics Corporation
30 Mar 21
THOUSAND OAKS, Calif. and SEATTLE, March 30, 2021 /PRNewswire/ -- Amgen Inc. (NASDAQ:AMGN) and Rodeo Therapeutics Corporation (Rodeo) today announced an agreement under which Amgen will acquire Rodeo, a privately held
Controlling Inflammation to Stop Disease
24 Mar 21
NEW YORK, March 24, 2021 /PRNewswire/ -- In a natural response to injury or infection, the body produces chemicals that trigger the immune system to release antibodies and proteins plus increase blood flow to the
FIVE PRIME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Five Prime Therapeutics - FPRX
11 Mar 21
Amgen To Present At The Oppenheimer 31st Annual Healthcare Conference
11 Mar 21

Calendar

8 Feb 21
18 Apr 21
31 Dec 21

Financial summary

Financial statements Chart AMGN financial data
Quarter (USD)
 Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from AMGEN earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 6.27B 6.27B 6.27B 6.27B 6.27B 6.27B
Cash burn (monthly) 940.33M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 3.39B n/a n/a n/a n/a n/a
Cash remaining 2.88B n/a n/a n/a n/a n/a
Runway (months of cash) 3.1 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Recent insider trades

AMGN insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 Apr 21 Ronald D Sugar Common Stock Sell Dispose S No Yes 249.98 1,000 249.98K 15,927
14 Apr 21 Ronald D Sugar Common Stock Option exercise Aquire M No No 71.64 1,000 71.64K 16,927
14 Apr 21 Ronald D Sugar Nqso Common Stock Option exercise Dispose M No No 71.64 1,000 71.64K 1,000
19 Mar 21 Robert A Bradway Common Stock Payment of exercise Dispose F No No 244.42 21,190 5.18M 589,262
19 Mar 21 Gordon Murdo Common Stock Payment of exercise Dispose F No No 244.42 8,989 2.2M 41,458
19 Mar 21 Jonathan P Graham Common Stock Payment of exercise Dispose F No No 244.42 4,360 1.07M 44,529
19 Mar 21 Nancy A. Grygiel Common Stock Payment of exercise Dispose F No No 244.42 435 106.32K 12,051
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

AMGN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

76.0% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 2139 2078 +2.9%
Opened positions 236 143 +65.0%
Closed positions 175 105 +66.7%
Increased positions 876 829 +5.7%
Reduced positions 748 772 -3.1%
13F shares
 Current Prev Q Change
Total value 101.49B 112.25B -9.6%
Total shares 437.38M 438.9M -0.3%
Total puts 4.08M 3.66M +11.7%
Total calls 3.65M 4.12M -11.4%
Total put/call ratio 1.1 0.9 +26.1%
Largest owners
 Shares Value Change
BLK Blackrock 47.81M $10.99B -0.4%
Vanguard 47.23M $10.86B -1.5%
Capital Research Global Investors 31.76M $7.3B -5.2%
STT State Street 30.09M $6.92B -3.8%
Primecap Management 16.98M $3.9B -2.5%
FMR 13.78M $3.17B -3.0%
MS Morgan Stanley 9.75M $2.24B +13.8%
Geode Capital Management 8.8M $2.02B -4.0%
NTRS Northern Trust 7.92M $1.82B -2.7%
WFC Wells Fargo & Co. 7.61M $1.75B +2.6%
Largest transactions
 Shares Bought/sold Change
Norges Bank 5.67M +5.67M NEW
JPM JPMorgan Chase & Co. 5.24M -3.03M -36.7%
Capital Research Global Investors 31.76M -1.74M -5.2%
STT State Street 30.09M -1.19M -3.8%
MS Morgan Stanley 9.75M +1.18M +13.8%
IVZ Invesco 2.17M -1.01M -31.8%
Boston Partners 972.58K +952.08K +4644.8%
UBS UBS Group AG - Registered Shares 3.24M +897.63K +38.3%
Capital International Investors 2.34M -759.45K -24.5%
Vanguard 47.23M -709.83K -1.5%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Celgene • Novelion Therapeutics • Spectrum Pharmaceuticals • Geron • Roche • Nektar Therapeutics • FibroGen • Exelixis • Sangamo Therapeutics • Protalix BioTherapeutics
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: AABP, AAER, accident, AECP, aflibercept, AISN, ALEN, Allergy, Alliance, ambition, AMD, AMP, amplify, amy, andChief, antibribery, anticorruption, antikickback, antiresorptive, arrive, Arthrex, autumn, AVEN, avoid, avoided, AVSOLA, backdoor, background, backlog, BARDA, BEIJERINCK, Biden, Biomedical, black, Blaylock, blended, BNP, body, BofA, bond, boosting, border, broadened, BSA, Businesswomen, calcimimetic, Career, Chinese, Cir, clarification, clear, coalition, CodeBreaK, cohort, college, combat, compulsory, concurrently, Connecticut, constitutionality, coordinated, copay, COVID, Crohn, culture, curfew, cutoff, cybersecurity, daily, deal, deceleration, dedesignate, deeper, Deficiency, defray, degeneration, dental, deplete, Deutsche, diagnosed, diminish, disciplined, dissemination, distancing, docetaxel, downturn, ease, ebb, ecosystem, edema, elderly, emphasize, Empowered, encompassing, endothelial, enduring, England, exacerbated, exacerbation, exempted, EYLEA, Fc, featured, Fed, fell, fleet, fluidity, foreseeable, foster, futility, globe, goal, Grygiel, Hampshire, healthy, HGRAC, HIV, hospital, hospitalized, ICOSL, ICS, IIIB, immune, immunodeficiency, immunosuppressive, impossible, incentivize, incident, Indian, inhaled, injury, inserted, instructing, intelligence, interfering, interlocutory, intermittent, internet, investee, joinder, Journal, KANJINTI, learning, left, legitimate, LGBTQ, linda, lockdown, logistical, louie, lp, macular, magnitude, makeup, manipulated, Maryland, MBA, medium, MFN, microscopic, mind, Minnesota, mission, mobile, motivate, motivating, multicenter, myriad, Nancy, nationwide, navigable, navigate, NAVIGATOR, NDA, neovascular, Nephew, neutrality, NIAID, nonbiologic, nonfederal, NYVEPRIA, occlusion, occupancy, OCS, OECD, Olpasiran, OneTen, onset, ORR, outbreak, output, outreach, overcome, overseen, pandemic, PASI, paused, pausing, physically, portal, postmarketing, precipitate, precipitated, prepaid, prepandemic, PRIDE, proliferation, proportion, proportionate, protocol, Purple, pushed, quartile, RBC, reassessment, recession, recommenced, redemption, reimpose, remote, remotely, renamed, representation, resource, respiratory, resurgence, resurgent, retaliatory, retinal, retinopathy, reverification, reward, rheumatology, RIABNITM, RINVOQ, RNA, root, RTOR, School, score, semiannual, Shank, Siebert, signification, siRNA, Smith, SoC, softened, sotorasib, speaker, sPGA, spread, Stafford, stakeholder, static, STELARA, Stivarga, strain, Subcontinent, surface, surge, tackle, talent, TBA, temperature, threat, timeline, Tokyo, training, trajectory, transmission, travel, turnover, UCLA, UDENYCA, unamortized, underemployment, underrepresentation, unemployment, uninsured, ustekinumab, vaccination, Van, vascular, VEGFR, vein, verified, virtual, Warehouse, Wegener, wet, wider, winter, workplace, writ, Xeljanz
Removed: AAA, advisory, Alzheimer, amyloid, atopic, augment, BACE, BLA, cardiac, construing, Cynthia, damage, decided, deCODE, deducting, Dermatology, Dezima, discontinuation, footprint, force, Galenica, Genentech, genome, grew, henderson, hold, Hope, hyperparathyroidism, impacting, Leonard, lessen, lesser, loan, margin, meline, Merck, Mimpara, MIRCERA, moot, moved, mutually, myosin, narrow, noncompliance, overhaul, pain, patentability, Patton, presidential, PROCRIT, properly, propose, reacquired, rebecca, reshaping, retained, revalue, SCAN, Schaeffer, sector, Servier, showing, sNDA, sorafenib, threshold, track, validation, vitamin
From filing 10-K 2020 FY

Financial reports

View all
10-K
2020 FY
Annual report
8 Feb 21
10-Q
2020 Q3
Quarterly report
28 Oct 20
10-Q
2020 Q2
Quarterly report
28 Jul 20
10-Q
2020 Q1
Quarterly report
30 Apr 20
10-K/A
2019 FY
Annual report (amended)
13 Feb 20
10-K
2019 FY
Annual report
12 Feb 20
10-Q
2019 Q3
Quarterly report
29 Oct 19
10-Q
2019 Q2
Quarterly report
30 Jul 19
10-Q
2019 Q1
Quarterly report
30 Apr 19
10-K
2018 FY
Annual report
13 Feb 19

Current reports

View all
8-K
Amgen Successfully Completes Acquisition of Five Prime Therapeutics
16 Apr 21
8-K
Amgen to Acquire Five Prime Therapeutics for Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide
4 Mar 21
8-K
Amgen Reports Fourth Quarter and Full Year 2020 Financial Results
2 Feb 21
8-K
Amgen Reports Third Quarter 2020 Financial Results
28 Oct 20
8-K
Entry into a Material Definitive Agreement
17 Aug 20
8-K
Amgen Announces Early Tender Results
13 Aug 20
8-K
Other Events
30 Jul 20
8-K
Amgen Reports Second Quarter 2020 Financial Results
28 Jul 20
8-K
Departure of Directors or Certain Officers
23 Jul 20
8-K
Departure of Directors or Certain Officers
23 Jul 20

Registration and prospectus

View all
SC TO-T/A
Third party tender offer statement (amended)
16 Apr 21
424B3
Prospectus supplement
15 Apr 21
SC TO-T/A
Third party tender offer statement (amended)
8 Apr 21
S-4/A
Registration of securities issued in business combination transactions (amended)
6 Apr 21
SC TO-T/A
Third party tender offer statement (amended)
6 Apr 21
SC TO-T/A
Third party tender offer statement (amended)
22 Mar 21
SC TO-T
Third party tender offer statement
18 Mar 21
SC TO-C
Information about tender offer
5 Mar 21
SC TO-C
Information about tender offer
4 Mar 21
SC TO-C
Information about tender offer
4 Mar 21

Proxies

View all
DEFA14A
Additional proxy soliciting materials
14 Apr 21
DEFA14A
Additional proxy soliciting materials
6 Apr 21
DEF 14A
Definitive proxy
6 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
PX14A6G
Letter to shareholders
15 Apr 20
DEFA14A
Additional proxy soliciting materials
13 Apr 20
DEFA14A
Additional proxy soliciting materials
7 Apr 20
DEF 14A
Definitive proxy
7 Apr 20
DEFA14A
Additional proxy soliciting materials
13 May 19

Other

View all
EFFECT
Notice of effectiveness
16 Apr 21
CT ORDER
Confidential treatment order
24 Oct 19
CT ORDER
Confidential treatment order
3 Jun 19
CT ORDER
Confidential treatment order
30 May 18
CT ORDER
Confidential treatment order
17 May 18
CT ORDER
Confidential treatment order
3 Dec 17
CT ORDER
Confidential treatment order
7 Sep 17
CT ORDER
Confidential treatment order
14 Aug 17
CT ORDER
Confidential treatment order
25 May 17
CT ORDER
Confidential treatment order
7 May 17

Ownership

View all
4
AMGEN / RONALD D SUGAR ownership change
15 Apr 21
4
AMGEN / Esteban Santos ownership change
22 Mar 21
4
AMGEN / DAVID M REESE ownership change
22 Mar 21
4
AMGEN / David Piacquad ownership change
22 Mar 21
4
AMGEN / Linda H. Louie ownership change
22 Mar 21
4
AMGEN / Lori A Johnston ownership change
22 Mar 21
4
AMGEN / Nancy A. Grygiel ownership change
22 Mar 21
4
AMGEN / Jonathan P Graham ownership change
22 Mar 21
4
AMGEN / Murdo Gordon ownership change
22 Mar 21
4
AMGEN / Robert A Bradway ownership change
22 Mar 21

Patents

View all
APP
Utility
Methods to Determine the Presence of an Antibody that Binds Modified Human Thymic Stromal Lymphopoietin (TSLP)
8 Apr 21
Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided.
APP
Utility
INTERLEUKIN-2 Muteins for the Expansion of T-regulatory Cells
1 Apr 21
Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production.
APP
Utility
Method for Making Injectable Pharmaceutical Compositions
1 Apr 21
The invention relates to methods for making injectable pharmaceutical compositions wherein particles present in the compositions are detected and analyzed, and the acceptance of the compositions is determined based on chemical and physical properties as well as toxicology and patient risks associated of the particles.
APP
Utility
Pacap Antibodies and Uses Thereof
1 Apr 21
The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies.
APP
Utility
Formulations of (+)-2-[1-(3-ETHOXY-4- METHOXY-PHENYL)-2-METHANESULFONYL- ETHYL]-4-ACETYLAMINOISOINDOLINE-1,3- Dione
1 Apr 21
Pharmaceutical compositions and single unit dosage forms of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate thereof, are provided herein.

Transcripts

View all
2020 Q4
Earnings call transcript
3 Feb 21
2020 Q3
Earnings call transcript
28 Oct 20
2020 Q2
Earnings call transcript
28 Jul 20
2020 Q1
Earnings call transcript
1 May 20
2019 Q4
Earnings call transcript
30 Jan 20
2019 Q3
Earnings call transcript
29 Oct 19
2019 Q2
Earnings call transcript
30 Jul 19
2019 Q1
Earnings call transcript
30 Apr 19
2018 Q4
Earnings call transcript
29 Jan 19
2018 Q3
Earnings call transcript
30 Oct 18

Reddit threads

View all